![Jeff Ryckman: The Netherlands has consistently produced excellent research on the ‘Good, Bad, and Ugly’ categories](https://oncodaily.com/pub/uploads/2023/09/Jeff-Ryckman-2-e1704219037424-1280x1070.jpeg)
Jeff Ryckman: The Netherlands has consistently produced excellent research on the ‘Good, Bad, and Ugly’ categories
Jeff Ryckman, Radiation Oncologist and Assistant Professor at West Virginia University, shared a post by Nina Niu Sanford, a Radiation Oncologist at UT Southwestern Medical Center, on X/Twitter:
“The Netherlands has consistently produced excellent research on the ‘Good, Bad, and Ugly’ categories. A 2020 publication, co-authored by several experts also on the 2023 pub, includes considerations for proximity to the verge.
In the ‘Good’ category, Dutch guidelines were linked to a 3x increase in surgery-first approaches without compromising OS. Additionally, for the ‘Ugly’ group, higher rates of pre-op CCRT in certain hospitals correlated with better 5-year OS outcomes.
Visit the article website.
The 2023 study combines ‘Good’ and ‘Bad’ elements. However, lacking specific details like T3c classification, distance to verge, and EMVI data, it’s challenging to apply these findings of the 2023 to individual patient scenarios.”
Quoting Nina Niu Sanford’s post:
“Just saw this rectal cancer study in JAMA Oncology – lots to digest.
Despite absolute 50% drop (87% to 37%) in use of neoadjuvant RT for lower risk (cT1-3, N0-1, MRF-) rectal cancers from 2011 to 2016, no difference in local recurrence & survival improved.”
Source: Jeff Ryckman/X and Nina Niu Sanford/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023